---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-366931"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-08-26T17:33:35+00:00"
generated_at: "2026-08-26T17:35:03.760572+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# FDA approves Revolution Medicines' RASONQUE for metastatic pancreatic adenocarcinoma

## Summary
- FDA approved RASONQUE (daraxonrasib) on Aug 26, 2026 for adult patients with metastatic pancreatic adenocarcinoma after prior systemic therapy or ineligible for multiagent therapy.
- Approval based on RASolute 302, a global randomized Phase 3 trial vs investigator's choice of cytotoxic chemotherapy in previously treated patients.
- Once-daily oral RASONQUE tablets now available in the U.S. for eligible patients; wholesale acquisition cost $39,800 for 30-day supply.
- This is the first FDA approval for Revolution Medicines' RAS inhibitor, marking a major commercial milestone.

## SEC filing metadata
- accession: 0001193125-26-366931
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-08-26T17:33:35+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/0001193125-26-366931-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/rvmd-20260826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-366931
- JSON: https://secwatch.observer/filing/0001193125-26-366931.json
- Plain text: https://secwatch.observer/filing/0001193125-26-366931.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.